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ABSTRACT 
Background: Glial cell-derived neurotrophic factor (GDNF) is a survival factor for 
dopaminergic neurons and a promising candidate for the treatment of Parkinson´s 
disease (PD). However, the delivery issue of the protein to the brain still remains 
unsolved. 
Purpose: The aim of the study was to investigate the effect of long-term delivery of 
encapsulated GDNF within microspheres. 
Methods: A single dose of microspheres containing 2.5 μg of GDNF was implanted 
intrastriatally in animals 2 weeks after a 6-hydroxydopamine lesion. 
Results: The amphetamine test showed a complete behavioral recovery after 16 weeks 
of treatment which was maintained until the end of the study (week 30). This effect was 
accompanied by an increase in dopaminergic striatal terminals and neuroprotection of 
dopaminergic neurons.  
Conclusions: The main achievement was the long-term neurorestoration in 
parkinsonian animals induced by encapsulated GDNF, suggesting that microspheres 
may be considered as a means to deliver GDNF for PD treatment. 
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ABREVIATIONS 
GDNF: glial cell-derived neurotrophic factor 
PD: Parkinson´s disease 
SNpc: substantia nigra pars compacta 
VTA: ventral tegmental area 
PLGA: poly-lactic-co-glycolic acid 
TH: tyrosine hydroxylase 
pTH: phosphorylated tyrosine hydroxylase 
6-OHDA: 6-hydroxydopamine 
BDA: biotinylated dextran amine 
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INTRODUCTION 
Glial cell derived neurotrophic factor (GDNF) was initially described as a potent 
neurotrophic factor for dopaminergic neurons, regarded as a promising therapeutic 
agent for PD 1. Several animal studies and a few clinical trials have set the requirements 
for proper GDNF treatment 2-4. Intracerebroventricular injection of GDNF in PD 
patients caused severe side effects, without improving parkinsonian symptoms 5, 6, 
probably because GDNF did not reach the target tissues 7. For these reasons, GDNF 
should be delivered locally to the caudate-putamen in humans or striatum in rodents 8. 
The results from two independent open-label trials showed that the sustained delivery of 
GDNF within the putamen using a mechanical pump reduced the motor symptoms and 
achieved a partial restoration of the nigrostriatal pathway 9, 10. These promising results 
were in contrast to the findings in the first double-blind placebo-controlled study in 
which GDNF infusion, at a lower dose and using a wider catheter, failed to improve 
motor symptoms in patients 11. The lack of efficacy in this trial, the appearance of 
antibodies against GDNF and cerebellar lesions in monkeys receiving very high doses 
of GDNF, resulted in the withdrawal of GDNF from all clinical tests. These studies 
concluded that a new delivery system should be developed before considering GDNF 
infusion in human patients. This has prompted researchers to seek alternative methods 
for long-term protein delivery. 
In the present study we propose the use of biodegradable and biocompatible non-toxic 
poly-lactic-co-glycolic acid (PLGA) microspheres for sustained GDNF delivery into the 
brain. The goal of this work was to asses whether a single low dose of 
microencapsulated GDNF would be sufficient to maintain long-term beneficial 
neuroestorative and/or neuroprotective effect in the partial 6-hydroxydopamine (6-
OHDA) rat model of PD. We provide evidence that encapsulated GDNF may be 
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delivered to the striatum, inducing a long-lasting recovery of lesion-induced motor 
impairment. Restoration of functional behavior is accompanied by striatal dopaminergic 
fiber sprouting, neuroprotection of dopaminergic cells at the SNpc level and an increase 
in tyrosine hydroxylase phosphorylation. 
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MATERIAL AND METHODS 
Microsphere preparation. 
Rat recombinant glycosylated GDNF was expressed and purified as previously 
described 12. GDNF-loaded microspheres were prepared using the solvent 
extraction/evaporation method utilizing TROMS technology 13. Fluorescent 
microspheres were prepared similarly but encapsulating rhodamine B isothiocyanate 
(0.1 mg) in the inner aqueous phase instead of GDNF. 
 
Animal procedures. 
Animals. Female Sprague-Dawley rats of 220-240 g were obtained from Harlan 
(Barcelona, Spain). Animals were kept in standard animal facilities with free access to 
food and water, in a temperature and humidity-controlled room with 12 h on–off light 
cycle. Procedures involving animals were in accordance with the guidelines established 
by the normative of the European Council (86/609/EEC).  
Experimental parkinsonism. Animals were anesthetized via an intraperitoneal injection 
of a 1:1 mixture of ketamine (75 mg/kg) and xylazine (10 mg/kg). Rats received two 6-
OHDA (Sigma) injections, each one of 10 µg in 5 µL of saline containing 0.1% 
ascorbic acid, into the striatum at the following coordinates relative to bregma 14: AP: 
+0.5 mm, ML: 2.5 mm DV: 5 mm and AP: -0.5 mm, ML: 4.2 mm, DV: 5 mm. 
Microsphere implantation. Stereotaxic surgery was performed 15 days after the 6-
OHDA lesion using the same coordinates. Each rat received a dose of 2.5 µg of GDNF 
in two implantations, each one comprising 1.5 mg of microspheres (1.25 µg of GDNF).  
Amphetamine test. The rotational behavior of the animals induced after an 
intraperitoneal injection of 5 mg/kg D-amphetamine (Sigma) was assessed on a 
computerized rotometer (Panlab).  
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Histological techniques 
Animals were perfused transcardially with a fixing solution containing 4% 
paraformaldehyde in 0.125 M phosphate buffer, pH 7.4. Coronal sections (40 µm thick) 
were obtained. Coronal sections (40mm thick) were use for immunohistochemistry. 
Histological techniques and optic density measurements were performed as described 
previously15. 
Statistical analysis 
Those data following a normal distribution were analyzed using independent Student´s t 
test and non-parametric data using a Wilcoxon test for independent samples. A p value 
< 0.05 was considered significant. 
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RESULTS 
Assessment of biodegradability of PLGA microspheres in vivo 
We first evaluated whether GDNF-microspheres were present 28 weeks after their 
implantation. Microspheres loaded with rhodamine were prepared and injected within 
the rat striatal parenchyma. Animals were sacrificed at different times and rhodamine-
microspheres were visualized by confocal microscopy (Fig. 1A). Between the first and 
second week there was a large decrease in the microsphere injection size that continued 
to decrease, at a lower rate, over time. Importantly, a significant amount of 
microspheres were still detectable at week 28th post-injection. 
Microencapsulated GDNF reverses altered motor behavior in a PD animal model  
To evaluate the long-term effect of encapsulated GDNF the partial 6-OHDA animal 
model was used. The extent of the lesion was assessed 13 days after the toxic 
administration by the amphetamine-induced rotational behavior test. Two days later, 
animals received an injection of either empty or GDNF-loaded microspheres. Striatal 
implantation of GDNF-microspheres significantly reduced amphetamine-induced 
ipsilateral rotational behavior (Fig. 1B) after 8 weeks of treatment. Furthermore, the 
imbalance in rotational behavior completely disappeared at week 16 and the recovery 
was maintained up to week 30. 
Effect of GDNF-microsphere treatment on TH-positive cells 
The effect of GDNF-microspheres at the striatal level was evaluated by TH 
immunohistochemistry. Intrastriatal injections of GDNF-microspheres induced profuse 
TH-immunoreactive (TH-ir) fiber sprouting surrounding the injection areas (Fig. 1C). In 
contrast, only the injection tract was visible around the injection sites of empty 
microspheres. Aberrant sprouting in the globus pallidus was not observed 16. 
Densitometric analysis at three different striatal rostrocaudal levels (Fig. 1D) showed a 
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22% increase in the area of TH immunoreactivity at the most caudal striatal levels. Our 
results suggest that these fibers are likely to arise from sprouting by the remaining 
terminals located within the ventral striatum and the nucleus accumbens. 
TH-ir neurons were counted in three sections throughout the central portion of the 
SNpc, at the level of the medial terminal nucleus of the accessory optic tract (Fig. 2A). 
A statistically significant 1.7-fold increase in the number of TH-ir cells was observed 
within the SNpc of animals treated with GDNF-microspheres (Fig. 2B). The degree of 
TH activity within these cells was studied by double immunofluorescence to detect the 
form of the enzyme TH phosphorylated at ser31 17, 18 (Fig. 2C). All cells detected were 
double labeled and fluorescence signal corresponding to pTH with respect to TH-
positive cells was quantified. A significant increase in this ratio at the SNpc level was 
found in GDNF-treated animals (Fig. 2D). This was not observed at the VTA level (Fig. 
2E). These results suggest that the improvement in behavior induced by GDNF-
microspheres could be due to both a neuroprotective effect on dopaminergic cells and 
an increase in TH activity. 
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DISCUSSION 
The results of the present study demonstrate that PLGA microspheres are an efficient 
vehicle for sustained delivery of neurotrophic factors to the brain. Biodegradable and 
biocompatible PLGA microspheres offer an interesting alternative and have already 
been used in clinical practice for the treatment of human gliomas 19, 20. Microspheres 
release drugs locally for an extended period of time, have a low risk of side effects and 
protect the encapsulated protein from degradation by tissue proteases. 
Several studies to determine neuroprotection have been performed by administrating 
GDNF prior to performing the 6-OHDA lesion 16, 21-24. While these studies are 
interesting for testing the efficacy of GDNF, the administration of the trophic factor 
after a lesion would have greater clinical relevance. For this reason, GDNF-
microspheres were implanted intrastriatally 14 days after the 6-OHDA lesion. At 28 
weeks post-implantation, microspheres were still present and the GDNF beneficial 
effect was preserved. GDNF was clearly detected by immunohistochemistry 5 weeks 
after microparticles implantation 15. In the present study, the immunohistochemistry 
procedure failed to detect the presence of GDNF, probably because the remaining 
protein was under the detection threshold of the technique. It may be assumed that very 
low GDNF doses are enough to maintain the beneficial effect as previous studies have 
demonstrated that protein withdrawal in PD patients 25 or GDNF viral expression switch 
off, reversed GDNF effect 26. The distribution of the trophic factor is another important 
issue. In this study, two intrastriatal microparticle injections were sufficient to promote 
a stable functional recovery of the 6-OHDA animal model. The number of microparticle 
injections may be increased for non-human primates or human brains with a larger 
putaminal volume.  
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An additional issue with GDNF-based therapy is the production of neutralizing 
antibodies against GDNF 11. An immune reaction against the E. coli unglycosylated 
recombinant protein used in the clinical trial could be responsible for the production of 
autoantibodies 27. To overcome this potential problem, glycosylated recombinant rat 
GDNF was used in our study 12 and the absence of anti-GDNF antibodies was 
confirmed 15. 
The low dose required in the present approach to achieve a functional effect was also 
remarkable. A total amount of 2.5 µg of GDNF was sufficient for the long-term effect 
of GDNF treatment. Considering that the human putamen volume is 171 times larger 
than the rat striatum 28 29, an estimation of the dose necessary for patients for a 28 week 
treatment would be 427 µg.  
The main achievement of this study was the stable long-term functional recovery in 
parkinsonian animals induced by GDNF treatment initiated after the 6-OHDA lesion. 
The results of this work indicate that microspheres should be considered as a method to 
deliver GDNF directly to the striatum for the treatment of PD. 
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LEGENDS 
 
Figure 1: Neurorestorative effect of GDNF-microspheres. (A) Degradation of 
rhodamine microspheres implanted intrastriatally. The same formulation of 
microspheres used for GDNF treatment was prepared and loaded with rhodamine. 
Rhodamine-microspheres were injected intrastriatally and the extent of the deposit was 
followed at different time intervals. Microspheres are still present at week 28. Scale bar: 
100 µm. (B) Amphetamine-induced rotation was performed 13 days after the 6-OHDA 
lesion. All animals that fulfilled the inclusion criteria (>9 full body turns per minute) 
received the injection of either empty or GDNF-loaded microspheres 48 h later. At 10 
weeks post-6-OHDA and 8 weeks after beginning the GDNF treatment, animals 
receiving GDNF-microspheres showed a significant improvement in their rotational 
behavior when compared to animals that received empty microspheres. The rotational 
response was completely reversed at week 16 and the recovery maintained until the end 
of the study (week 30). Control animals treated with empty microspheres (open circles), 
n = 6; animals treated with GDNF microspheres (filled circles), n = 8. *p<0.05. (C) TH 
immunohistochemistry was performed in animals sacrificed 30 weeks after 6-OHDA 
lesion. Images at the striatal level of the two injection sites show an increase in TH-
positive fiber density surrounding the GDNF-microspheres deposits that is not 
detectable around the empty-microspheres deposits in lesioned animals. Scale bar: 1 
mm. (D) Quantification of the TH-positive fiber density at three different rostrocauldal 
levels. *p<0.05. 
 
Figure 2: GDNF effect in the substantia nigra pars compacta. (A) 
Immunohistochemistry for TH revealed an increase in the number of surviving cells in 
the SNpc of GDNF-treated compared to empty-microspheres-treated animals 30 weeks 
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after the 6-OHDA lesion. (B) Quantification of TH-positive neurons from the SNpc 
showed a statistically significant increase in the number of cells present in animals 
treated with GDNF microspheres compared to animals that received empty 
microspheres. Scale bar: 1 mm. Wilcoxon test *p<0.05. (C) Double 
immunohistochemistry for TH and pTH showed that all cells were double labeled and 
presented an increase in pTH level. Quantification of fluorescence intensity of pTH with 
respect to the total amount of TH at the level of SN (D) and VTA (E) showed a 
significant increase of pTH in TH-ir neurons from the SNpc of GDNF-treated animals 
compared to the contralateral side. Scale bar: 20 μm. t-Student *p<0.05. 
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